Pancreatic Cancer Pipeline Appears Robust With 290+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's, "Pancreatic Cancer Pipeline Insight 2025" report provides comprehensive insights about 290+ companies and 300+ pipeline drugs in Pancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Pancreatic Cancer Pipeline Report to explore emerging therapies, key Pancreatic Cancer Companies, and future Pancreatic Cancer treatment landscapes @ Pancreatic Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Pancreatic Cancer Pipeline Report

* In April 2025, Nelson Yee announced phase II clinical study to investigate the efficacy and tolerability of a combination of liposomal irinotecan (nal-IRI) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-nal-IRI) for treatment of patients with locally advanced pancreatic carcinoma (LAPC).
* In April 2025, InxMed (Shanghai) Co. Ltd announced a study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising two phases: dose confirmation phase and dose expansion phase. The objective of the dose confirmation phase is to determine the recommended Phase II dose (RP2D) of IN10018+ standard chemotherapy (albumin-bound paclitaxel + gemcitabine) and IN10018 + KN046 + standard chemotherapy in subjects with advanced pancreatic cancer. The dose expansion phase will further explore the antitumor activities and safety of combination therapy in subjects with advanced pancreatic cancer.
* DelveInsight's Pancreatic Cancer pipeline report depicts a robust space with 290+ active players working to develop 300+ pipeline therapies for Pancreatic Cancer treatment.
* The leading Pancreatic Cancer Companies such as ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics , and others.
* Promising Pancreatic Cancer Pipeline Therapies such as Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine , and others.

Stay ahead with the most recent pipeline outlook for Pancreatic Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pancreatic Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Pancreatic Cancer Emerging Drugs Profile

* Pamrevlumab: FibroGen

Pamrevlumab is a potential first-in-class antibody being developed by FibroGen that inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. The U.S. Food and Drug Administration has granted Orphan Drug Designation, and Fast Track designation to Pamrevlumab for the treatment of patients with pancreatic cancer. Currently it is in Phase III stage of clinical trial evaluation to treat Pancreatic Cancer.

* Devimistat: Cornerstone Pharmaceuticals

CPI-613 (devimistat), is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth. Cancer progresses because it utilizes the mitochondria - the energy machinery of the cells - to generate the building blocks of the next tumor in order to fuel cancer growth and proliferation. Because it is designed to be highly specific, minimally toxic and effective against a wide variety of cancers, devimistat can be used for recurrent and hard-to-treat cancers, including on a chronic basis; it may also enhance the sensitivity of cancer cells to other treatment modalities, including chemotherapy. Currently, the drug is in Phase III stage of its development for the treatment of pancreatic cancer.

* Masitinib: AB Science

Masitinib is a highly selective inhibitor of mast cell which gives therapeutic benefit by impacting on mast cell related remodeling of the tumor microenvironment. Masitinib is being developed in combination with chemotherapies for treatment of malignancies through its immunotherapeutic properties. The increased mast cell activity within the tumor microenvironment can promote disease progression through release of numerous pro-tumoral mediators, down-regulate the immune response to tumors, and modulation of macrophages towards a pro-tumoral state. The inhibition of the mast cell activity results in anti-tumor effect.

* SBP-101: Panbela Therapeutics

Ivospemin (SBP-101) is a proprietary polyamine analogue that, due to its unique chemical structure. It inhibits both S-adenosylmethionine decarboxylase 1 (AMD1) and ornithine decarboxylase 1 (ODC1), two key enzymes in polyamine biosynthesis, lowering intracellular polyamine concentrations and slowing or preventing targeted cell growth and division. Ivospemin provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity. The polyamine pathway at complementary junctions alter the disease. In particular, the drug have the potential to suppress and prevent tumor growth, enhance anti-tumor activity of other anti-cancer agents, and modulate the immune system. Currently, the drug is in Phase II/III stage of its development for the treatment of pancreatic cancer.

* TAS-102: Taiho Pharmaceutical Co., Ltd.

TAS-102 (Lonsurf) is an oral anticancer drug, which utilizes the combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity and differs from conventional fluoropyrimidines. FTD is an antineoplastic nucleoside analogue, which is incorporated directly into the DNA, thereby interfering with the function of DNA. The blood concentration of FTD is maintained via TPI, which is an inhibitor of the FTD-degrading enzyme, thymidine phosphorylase. The drug is currently in Phase II trial for the pancreatic cancer.

* RAIN-32: Rain Oncology

RAIN-32 (Milademetan), an oral small molecule, inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, and loss of an MDM2 regulator or other mechanism. The company commenced an additional Phase II trial in a multicenter, single arm, open-label, and basket trial evaluating milademetan for the treatment of MDM2-amplified advanced solid tumors (MANTRA-2) including pancreatic cancer.

* IMX-110: Immix Biopharma

IMX-110 is a Tissue-Specific Therapeutic Trademark built on ImmixBio's TME Normalization Trademark Technology encapsulating a poly-kinase inhibitor and apoptosis inducer delivered deep into the tumor micro-environment, or TME. ImmixBio's TME Normalization Technology enables IMX-110 to circulate in the bloodstream, then exit through porous tumor blood vessels, and accumulate in the TME. IMX-110 then simultaneously attacks all 3 components of the TME (cancer associated fibroblasts, or CAFs; tumor-associated macrophages/immune cells, or TAMs, and cancer itself), severing the critical lifelines between the tumor and its metabolic and structural support. IMX-110's TME Normalization Technology causes tumor apoptosis, a non-inflammatory tumor-cell death (vs. necroptosis, which results in repeat reignition of the inflammatory cascade leading to tumor progression).

The Pancreatic Cancer Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer treatment.
* Pancreatic Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Cancer market.

Explore groundbreaking therapies and clinical trials in the Pancreatic Cancer Pipeline. Access DelveInsight's detailed report now! @ New Pancreatic Cancer Drugs [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Pancreatic Cancer Companies

ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics , and others

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Pancreatic Cancer Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Unveil the future of Pancreatic Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Pancreatic Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Pancreatic Cancer Pipeline Report

* Coverage- Global
* Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Pancreatic Cancer Companies- ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics , and others.
* Pancreatic Cancer Pipeline Therapies- Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine , and others.

Which companies are leading the race in Pancreatic Cancer drug development? Find out in DelveInsight's exclusive Pancreatic Cancer Pipeline Report-access it now! @ Pancreatic Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Pancreatic Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Pancreatic Cancer - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Pamrevlumab: FibroGen
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Niraparib: Innovent Biologics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* CT041: CARsgen Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* ONC 212: Oncoceutics
* Drug profiles in the detailed report.....
* Inactive Products
* Pancreatic Cancer Key Companies
* Pancreatic Cancer Key Products
* Pancreatic Cancer- Unmet Needs
* Pancreatic Cancer- Market Drivers and Barriers
* Pancreatic Cancer- Future Perspectives and Conclusion
* Pancreatic Cancer Analyst Views
* Pancreatic Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pancreatic-cancer-pipeline-appears-robust-with-290-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.